Prediction of Human Pharmacokinetic Profile After Transdermal Drug Application Using Excised Human Skin.
Although several mathematical models have been reported for the estimation of human plasma concentration profiles of drug substances after dermal application, the successful cases that can predict human pharmacokinetic profiles are limited. Therefore, the aim of this study is to investigate the prediction of human plasma concentrations after dermal application using in vitro permeation parameters obtained from excised human skin. The in vitro skin permeability of 7 marketed drug products was evaluated. The plasma concentration-time profiles of the drug substances in humans after their dermal application were simulated using compartment models and the clinical pharmacokinetic parameters. The transdermal process was simulated using the in vitro skin permeation rate and lag time assuming a zero-order absorption. These simulated plasma concentration profiles were compared with the clinical data. The result revealed that the steady-state plasma concentration of diclofenac and the maximum concentrations of nicotine, bisoprolol, rivastigmine, and lidocaine after topical application were within 2-fold of the clinical data. Furthermore, the simulated concentration profiles of bisoprolol, nicotine, and rivastigmine reproduced the decrease in absorption due to drug depletion from the formulation. In conclusion, this simple compartment model using in vitro human skin permeation parameters as zero-order absorption predicted the human plasma concentrations accurately.
Drug Metabolism and Pharmacokinetics Research Laboratories, Takeda Pharmaceutical Company Ltd., 26-1, Muraoka-Higashi 2-chome, Fujisawa, Kanagawa, Japan. Electronic address: syunsuke.yamamoto@takeda.com.
Syunsuke
S
Yamamoto
Analytical Development, Pharmaceutical Sciences, Takeda Pharmaceutical Company Ltd., 26-1, Muraoka-Higashi 2-chome, Fujisawa, Kanagawa, Japan.
Masatoshi
M
Karashima
Analytical Development, Pharmaceutical Sciences, Takeda Pharmaceutical Company Ltd., 26-1, Muraoka-Higashi 2-chome, Fujisawa, Kanagawa, Japan.
Yuta
Y
Arai
Drug Metabolism and Pharmacokinetics Research Laboratories, Takeda Pharmaceutical Company Ltd., 26-1, Muraoka-Higashi 2-chome, Fujisawa, Kanagawa, Japan.
Kimio
K
Tohyama
Drug Metabolism and Pharmacokinetics Research Laboratories, Takeda Pharmaceutical Company Ltd., 26-1, Muraoka-Higashi 2-chome, Fujisawa, Kanagawa, Japan.
Nobuyuki
N
Amano
D000279:Administration, Cutaneous; D003198:Computer Simulation; D005260:Female; D006801:Humans; D008954:Models, Biological; D012867:Skin / Q000378:metabolism*; D012869:Skin Absorption
absorption; in vitro/in vivo correlations; mathematical model; pharmacokinetics; skin; transdermal